Tarsons Products Quarterly Results for Trading Insights
In Mar 2026, Tarsons Products (TARSONS) reported revenue ₹128 Cr and net profit ₹4 Cr — revenue +9.4% YoY. Browse TARSONS annual financials for revenue, profit, balance sheet and cash flow data.
TARSONS Quarterly Results — Revenue, Profit & EPS Highlights
Tarsons Products latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Tarsons Products screener.
- Revenue of ₹128 Cr in Mar 2026 (+18.5% vs Sept 2025, +9.4% vs Mar 2025)
- Net Profit of ₹4 Cr in Mar 2026 (+33.3% vs Sept 2025, -60.0% vs Mar 2025)
- EBITDA of ₹41 Cr in Mar 2026 (+24.2% vs Sept 2025)
- Operating Margin of 28.0% in Mar 2026 (+1.0pp vs Sept 2025)
- Earnings Per Share of ₹0.79 in Mar 2026 (+27.4% vs Sept 2025)
Tarsons Products Quarterly Results — Revenue, EBITDA, Net Profit & EPS
TARSONS quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 128 | 108 | 117 | 95 | 116 | 18.5% | 9.4% |
| Net Profit (₹ Cr) | 4 | 3 | 10 | 2 | 5 | - | - |
| EBITDA (₹ Cr) | 41 | 33 | 41 | 28 | 39 | - | - |
| EPS (₹) | 0.79 | 0.62 | 1.92 | 0.34 | 0.95 | - | - |
| Operating Margin (%) | 28.0% | 27.0% | 33.0% | 27.0% | 28.0% | - | - |
TARSONS Share Price Trend — 1-Year Movement Across Quarterly Results
Tarsons Products 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore TARSONS share price data to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
TARSONS vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Tarsons Products latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹469,405.89 Cr | 1941.1 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 171.8 |
|
Divis Laboratories
Mar 2026 |
₹194,269.91 Cr | 7248.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 256.0 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹191,454.40 Cr | 4961.5 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 431.1 |
|
Zydus Life Science
Mar 2026 |
₹115,616.29 Cr | 1108.7 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 87.6 |
|
Cipla
Mar 2026 |
₹114,318.19 Cr | 1410.6 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 205.3 |
All amounts in ₹ Crores